A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Encaleret (Primary)
- Indications Hypocalcaemia; Hypoparathyroidism
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors BridgeBio Pharma; Calcilytix therapeutics
Most Recent Events
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 10 Oct 2023 Results presented in the bridgebio pharma Media Release.
- 10 Oct 2023 According to a BridgeBio Pharma media release, the Company plans additional presentations related to the program at the upcoming American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting.